{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:44:31Z","timestamp":1787957071159,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Case:<\/jats:title>\n                    <jats:p>Duchenne\/Becker muscular dystrophy (DMD\/BeMD) is caused by a loss of dystrophin leading to muscular weakness. Glucocorticoids are used to delay loss of muscle strength but frequently result in osteoporosis and fractures. Bisphosphonates are the drug of choice, and there are limited data on the efficacy of denosumab. We describe 2 patients who were treated with denosumab and had stable to improved bone density with no side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Denosumab can be considered for the treatment of osteoporosis in adults with DMD\/BeMD, especially when the response to bisphosphonates is not satisfactory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2106\/jbjs.cc.21.00664","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T14:03:23Z","timestamp":1647439403000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Denosumab on Bone Health in Adult Patients with Duchenne\/Becker Muscular Dystrophy"],"prefix":"10.2106","volume":"12","author":[{"given":"Chermaine","family":"Hung","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine D.","family":"Mathews","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Iowa, Iowa City, Iowa"},{"name":"Department of Pediatrics, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2405-8963","authenticated-orcid":false,"given":"Amal","family":"Shibli-Rahhal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Iowa, Iowa City, Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,1]]},"reference":[{"key":"bib1-20240805","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul Disord."},{"key":"bib2-20240805","first-page":"CD003725","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"bib3-20240805","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1210\/er.2018-00097","article-title":"Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy","volume":"39","author":"Hardy","year":"2018","journal-title":"Endocr Rev."},{"key":"bib4-20240805","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","article-title":"Bone mineral density and fractures in boys with Duchenne muscular dystrophy","volume":"20","author":"Larson","year":"2000","journal-title":"J Pediatr Orthop."},{"key":"bib5-20240805","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1469-8749.2002.tb00272.x","article-title":"Fracture prevalence in Duchenne muscular dystrophy","volume":"44","author":"McDonald","year":"2002","journal-title":"Dev Med Child Neurol."},{"key":"bib6-20240805","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology."},{"key":"bib7-20240805","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","article-title":"Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar database","volume":"76","author":"Joseph","year":"2019","journal-title":"JAMA Neurol."},{"key":"bib8-20240805","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11914-018-0468-2","article-title":"Targeting the muscle-bone unit: filling two needs with one deed in the treatment of Duchenne muscular dystrophy","volume":"16","author":"Boulanger Piette","year":"2018","journal-title":"Curr Osteoporos Rep."},{"key":"bib9-20240805","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"bib10-20240805","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","article-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"96","author":"Ward","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"bib11-20240805","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"bib12-20240805","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","article-title":"The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy","volume":"23","author":"Sbrocchi","year":"2012","journal-title":"Osteoporos Int."},{"key":"bib13-20240805","first-page":"91","article-title":"Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study","volume":"71","author":"Allington","year":"2005","journal-title":"Acta Orthop Belg."},{"key":"bib14-20240805","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.23948","article-title":"Bone density and alendronate effects in Duchenne muscular dystrophy patients","volume":"49","author":"Houston","year":"2014","journal-title":"Muscle Nerve."},{"key":"bib15-20240805","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.apmr.2004.04.021","article-title":"Alendronate in the treatment of low bone mass in steroid-treated boys with Duchenne muscular dystrophy","volume":"86","author":"Hawker","year":"2005","journal-title":"Arch Phys Med Rehabil."},{"key":"bib16-20240805","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.4158\/EP-2020-0073","article-title":"Effects of bisphosphonates on osteoporosis induced by Duchenne muscular dystrophy: a prospective study","volume":"26","author":"Zheng","year":"2020","journal-title":"Endocr Pract."},{"key":"bib17-20240805","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract."},{"key":"bib18-20240805","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1759720X18805759","article-title":"New and emerging concepts in the use of denosumab for the treatment of osteoporosis","volume":"10","author":"Lewiecki","year":"2018","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"bib19-20240805","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2106\/JBJS.CC.17.00190","article-title":"Efficacy of denosumab for glucocorticoid-induced osteoporosis in an adolescent patient with Duchenne muscular dystrophy: a case report","volume":"8","author":"Kumaki","year":"2018","journal-title":"JBJS Case Connect."},{"key":"bib20-20240805","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"bib21-20240805","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"bib22-20240805","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: an emerging therapy in pediatric bone disorders","volume":"15","author":"Boyce","year":"2017","journal-title":"Curr Osteoporos Rep."},{"key":"bib23-20240805","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J Musculoskelet Neuronal Interact."},{"key":"bib24-20240805","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","article-title":"Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease","volume":"98","author":"Grasemann","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"bib25-20240805","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","journal-title":"Pediatr Blood Cancer."},{"key":"bib26-20240805","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","journal-title":"J Bone Miner Metab."},{"key":"bib27-20240805","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26926","article-title":"Denosumab treatment in aneurysmal bone cyst: evaluation of nine cases","volume":"65","author":"Kurucu","year":"2018","journal-title":"Pediatr Blood Cancer."},{"key":"bib28-20240805","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.otsr.2019.04.028","article-title":"Denosumab for treating aneurysmal bone cysts in children","volume":"105","author":"Raux","year":"2019","journal-title":"Orthop Traumatol Surg Res."},{"key":"bib29-20240805","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"bib31-20240805","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the Denosumab and Teriparatide Follow-up study (DATA-Follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone."}],"container-title":["JBJS Case Connector"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.CC.21.00664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:39:27Z","timestamp":1787751567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.CC.21.00664"}},"subtitle":["A Report of 2 Cases"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.cc.21.00664","relation":{},"ISSN":["2160-3251"],"issn-type":[{"value":"2160-3251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}